RNA

Ginkgo Bioworks has announced a collaboration with Pfizer focused on the discovery of RNA-based drug candidates.   In the collaboration, Pfizer will leverage Ginkgo’s proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. Ginkgo will receive an upfront payment and is eligible to receive research fees and development […]

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this free roundtable to learn about challenges related to the delivery of RNA […]

RNA therapeutics company SiSaf has published positive safety and efficacy data for its siRNA therapy for Autosomal Dominant Osteopetrosis 2 (ADO2). The data demonstrate that siRNA complexed with SiSaf’s silicon stabilised hybrid lipid nanoparticles (sshLNP) was able to significantly downregulate expression of an ADO2-specific mutant gene. The company says these results could have significant translational impact on […]

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this free roundtable to learn about challenges related to the delivery of RNA […]

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this free roundtable to learn about challenges related to the delivery of RNA […]

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this free roundtable to learn about challenges related to the delivery of RNA […]

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this free roundtable to learn about challenges related to the delivery of RNA […]

Samir Ounzain, PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. Over the next two decades, it is quite possible that most […]

ProQR Therapeutics and Laboratoires Théa have announced an agreement in which ProQR will divest its late-stage ophthalmic assets, sepofarsen and ultevursen, to Théa. Under the terms of the agreement, ProQR will receive an initial payment of €12.5M and will also be eligible for up to €135M in further development, regulatory, and commercial payments. “We are […]

Alnylam Pharmaceuticals has revealed results from its Phase I study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension. The results are published in the New England Journal of Medicine (NEJM). The key data showed that compared to placebo, zilebesiran was associated with dose-dependent reductions in serum […]

Evotec has received a $1.7 million grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing. Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses. Henipavirus is a genus of zoonotic viruses that can cause fatal encephalitis in humans. The genus comprises six different […]

Integrated DNA Technologies (IDT) has launched a new solution to optimise operational efficiency and the identification of solid cancer tumours.   The IDT Archer FUSIONPlex Core Solid Tumor Panel is a first-line cancer research testing solution that has been expanded and optimised for additional single nucleotide variant (SNV) and indel coverage to streamline fusion detection and […]

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. Diana Spencer spoke to Raphael Townshend, PhD, Founder and CEO of Atomic AI, about the advantages of combining two such exciting technologies. Artificial Intelligence (AI) has been enthusiastically adopted by the drug discovery sector as a tool for […]

In a step forward for genetic engineering and synthetic biology, US researchers have modified E coli bacteria to be immune to infection by all natural viruses tested so far. The team used two safeguard methods to prevent the bacteria and their modified genes from escaping into the wild. The work promises to reduce the threats […]

The success of messenger RNA or mRNA vaccines in the fight against the global SARS-CoV-2 crisis brings a new era of vaccine development. In vitro transcription, or IVT, is a complex reaction, requiring key components like an RNA polymerase, nucleotides, and a DNA template to make each mRNA. By partnering with a supplier like Thermo […]

In this listicle, Thermo Fisher Scientific outlines five measures to help you ensure consistency in your workflow and produce reproducible, high-quality batches of IVT mRNA at scale. The success of messenger RNA (mRNA) vaccines in combatting the global SARS-CoV-2 crisis brings a new era of vaccine development. Applications of in vitro transcribed (IVT) RNA in […]